Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Conferences

Conference Coverage

Conference Listing

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

 in 2023, where she produces content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

Articles

EHR penicillin allergy flags do not often match allergist assessments, highlighting the need for improved evaluation processes.

Misalignment Between EHR Penicillin Allergy Flags, Allergist Assessments Signals Need for Improved Documentation

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

Although most clinicians used intraocular pressure (IOP) as a continuous risk factor in glaucoma treatment decisions, the historical cutoff may still be used.

Clinicians May Still Be Using Historical IOP Cutoff for Decision-Making

Videos

Flu vaccination in older adults may prevent hospitalizations and cardiovascular events, saving lives and reducing health care costs, according to Marco del Riccio, MD.

Influenza Vaccination in Older Adults Could Save Lives, Reduce Costs: Marco del Riccio, MD

Sabrina McCrear is an assistant editor for 

 (AJMC®), which she joined in 2025. She produces written and video content across a range of disease areas and manages social media platforms for 

Sabrina holds a B.A. in Journalism with a minor in Biology from Howard University in Washington, D.C. You can connect with her on 

Lower income and higher social deprivation were associated with increased heart failure and arrhythmia risk in patients with hypertrophic cardiomyopathy.

Social Determinants of Health Linked to Worse Outcomes in Hypertrophic Cardiomyopathy

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

1.125rem

David Kuter, MD, DPhil, is director of clinical hematology at Massachusetts General Hospital and professor of medicine at Harvard Medical School.

The most pressing questions in ITP involve finding a cure and developing treatments safe for use during pregnancy.

Focus Turns to Unmet Needs in ITP, Related Autoimmune Diseases After Rilzabrutinib Approval: David Kuter, MD, DPhil

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

Rilzabrutinib Offers a New, Well-Tolerated Option for Patients With ITP: David Kuter, MD, DPhil

Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.

New First-in-Class ITP Therapy May Transform Clinical Practice: David Kuter, MD, DPhil